Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol 2023; 44(03): 345-352
DOI: 10.1055/s-0043-1761412
Original Article

Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study

Sobiya Mahnaz Ayesha
1   Department of Pathology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
,
Monalisa Hui
1   Department of Pathology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
,
Shantveer G Uppin
1   Department of Pathology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
,
Megha Shantveer Uppin
1   Department of Pathology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
,
Shubhranshu Jena
2   Department of Surgical Oncology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
,
Rajsekhar Shanthappa Patil
2   Department of Surgical Oncology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
,
Ranganath Ratnagiri
2   Department of Surgical Oncology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
,
Tara Roshni Paul 
1   Department of Pathology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction A specific subset of papillary microcarcinoma of thyroid (PMC) can metastasize regionally and to distant organs, and thus, have a significant effect on the overall survival of the patient cohort.

Objectives We aim to analyze the prognostic significance of various clinicopathologic parameters including BRAFV600E mutation by immunohistochemistry in PMC, in order to identify the subset of cases with aggressive behavior.

Materials and Methods Data regarding the PMC cases was retrieved retrospectively from medical records. The clinicopathologic factors like age, tumor size, focality, capsular invasion, histologic subtype, lymphovascular invasion, perithyroidal fat invasion (PTFI), lymph node (LN) metastasis, and distant metastasis were studied in depth. Tissue microarray was constructed to perform immunohistochemistry with CK19 and BRAFV600E. Information regarding overall survival (OS) and development of metastasis, if any, was noted. Chi-squared test was performed to know the association between various factors. To determine odds ratio, logistic regression was done. Survival analysis was done using Kaplan–Meier and Cox-regression analysis.

Results PMC was diagnosed in 48 patients (M:F = 1:2.4), between 22 and 70 years of age (median = 46.5 years). Chi-squared test showed significant association of fibrosis with tumor size more than or equal to 0.5 cm, infiltrative borders, PTFI, and LN metastasis. Tumor size was also associated with infiltrative borders; and LN metastasis with PTFI. BRAFV600E positivity showed significant association with histologic pattern, PTFI and distant metastasis. On logistic regression, tumor size showed significantly increased odds ratio with presence of fibrosis and infiltrative borders. Presence of fibrosis also showed significant association with infiltrative borders and LN metastasis. BRAF V600E had significantly increased odds ratio with histologic pattern, both on univariate and multivariate logistic regression. Kaplan–Meier analysis revealed significantly reduced OS with presence of LN metastases (p-value = 0.050, log-rank test). Cox-regression did not yield a significant hazard ratio for the various factors studied.

Conclusion This study shows association of LN metastasis with intratumoral fibrosis, PTFI and reduced OS. Intratumoral fibrosis was also associated with tumor size more than 5mm, infiltrative borders and PTFI. Increasing tumor size and infiltrative borders also showed an association. In addition, BRAFV600E positivity was found to be associated with histologic pattern, PTFI and distant metastasis.

Keywords

thyroid - papillary microcarcinoma - prognosis - BRAFV600E - lymph node metastasis

Authors' Contributions

Sobiya Mahnaz Ayesha contributed to designing, definition of intellectual content; literature search, experimental studies, data acquisition, data analysis, statistical analysis, manuscript preparation, editing and review; Monalisa Hui helped in designing, definition of intellectual content; literature search, experimental studies, data analysis, statistical analysis, manuscript preparation, editing and review; Shantveer G Uppin helped in conceptualization, designing, definition of intellectual content, literature search, experimental studies, data analysis, statistical analysis, manuscript preparation, editing and review; Megha Shantveer Uppin and Tara Roshni Paul helped in definition of intellectual content, manuscript preparation, editing, and review; Shubhranshu Jena, Rajsekhar Shanthappa Patil, and Ranganath Ratnagiri contributed to definition of intellectual content, clinical studies, manuscript preparation, editing, and review. Shantveer G Uppin has provided guarantee.


Ethics approval obtained from the institutional ethics committee (letter no.EC/NIMS/2809/2021).


Supplementary Material



Publication History

Article published online:
12 May 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Rosai J, Albores Saavedra J, Asioli S. et al. Papillary thyroid carcinoma. ln: Lloyd RV, Osamura RY, Kloppel G, Rosai J, eds. WHO Classification of Tumors of Endocrine Organs. 4th edition. Lyon: IARC; 2017: 81-91
    Google Scholar
  • 2 Corn S, Mitmaker E, Tabah R, Ciarallo A, How J. Incidental thyroid uptake on PET scanning: epidemiology, clinical significance, and management challenge. J Cancer Metastasis Treat 2021; 7: 41
    Google Scholar
  • 3 Nishimori H, Tabah R, Hickeson M, How J. Incidental thyroid “PETomas”: clinical significance and novel description of the self-resolving variant of focal FDG-PET thyroid uptake. Can J Surg 2011; 54 (02) 83-88
    CrossrefPubMedGoogle Scholar
  • 4 Shi C, Guo Y, Lv Y. et al. Clinicopathological features and prognosis of papillary thyroid microcarcinoma for surgery and relationships with the BRAFV600E mutational status and expression of angiogenic factors. PLoS One 2016; 11 (12) e0167414
    CrossrefPubMedGoogle Scholar
  • 5 Cooper DS, Doherty GM, Haugen BR. et al; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19 (11) 1167-1214 [published correction appears in Thyroid. 2010 Jun;20(6):674–5]
    CrossrefPubMedGoogle Scholar
  • 6 Leboulleux S, Tuttle RM, Pacini F, Schlumberger M. Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?. Lancet Diabetes Endocrinol 2016; 4 (11) 933-942
    CrossrefPubMedGoogle Scholar
  • 7 Kluijfhout WP, Pasternak JD, Kwon JS. et al. Microscopic positive tumor margin does not increase the risk of recurrence in patients with T1-T2 well-differentiated thyroid cancer. Ann Surg Oncol 2016; 23 (05) 1446-1451
    CrossrefPubMedGoogle Scholar
  • 8 Bernstein J, Virk RK, Hui P. et al. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis. Thyroid 2013; 23 (12) 1525-1531
    CrossrefPubMedGoogle Scholar
  • 9 Lee X, Gao M, Ji Y. et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009; 16 (02) 240-245
    CrossrefPubMedGoogle Scholar
  • 10 Marchetti I, Iervasi G, Mazzanti CM. et al. Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis. Thyroid 2012; 22 (03) 292-298
    CrossrefPubMedGoogle Scholar
  • 11 John AM, Jacob PM, Oommen R, Nair S, Nair A, Rajaratnam S. Our experience with papillary thyroid microcancer. Indian J Endocrinol Metab 2014; 18 (03) 410-413
    CrossrefPubMedGoogle Scholar
  • 12 Fonseca D, Murthy SS, Tagore R. et al. BRAF status in the variants of papillary thyroid carcinoma. Int J Head Neck Pathol. 2018; 1: 41-47
    CrossrefGoogle Scholar
  • 13 Tagore KR, Ramineni Asok Kumar S. Unusual presentation of papillary microcarcinoma of thyroid as thigh mass. Case Rep Pathol 2011; 2011: 651701
    PubMedGoogle Scholar
  • 14 Nimmagadda A, Krishna Mohan VS, Manthri R, Kalawat TC. Unusual metastases in papillary microcarcinoma of thyroid. Indian J Nucl Med 2019; 34 (01) 32-34
    CrossrefPubMedGoogle Scholar
  • 15 Karkuzhali P, Yogambal M, Kumar M. An Indian tertiary care hospital scenario of papillary carcinoma of thyroid. J Clin Diagn Res 2017; 11 (06) EC26-EC29
    PubMedGoogle Scholar
  • 16 Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003; 98 (01) 31-40
    CrossrefPubMedGoogle Scholar
  • 17 Lin KD, Lin JD, Huang HS, Jeng LB, Ho YS. Skull metastasis with brain invasion from thyroid papillary microcarcinoma. J Formos Med Assoc 1997; 96 (04) 280-282
    PubMedGoogle Scholar
  • 18 Liou MJ, Lin JD, Chung MH, Liau CT, Hsueh C. Renal metastasis from papillary thyroid microcarcinoma. Acta Otolaryngol 2005; 125 (04) 438-442
    CrossrefPubMedGoogle Scholar
  • 19 Park YJ, Kim YA, Lee YJ. et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck 2010; 32 (01) 38-45
    CrossrefPubMedGoogle Scholar
  • 20 Tran B, Roshan D, Abraham E. et al. An analysis of the American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma. J Clin Endocrinol Metab 2018; 103 (06) 2199-2206
    CrossrefPubMedGoogle Scholar
  • 21 Niemeier LA, Kuffner Akatsu H, Song C. et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 2012; 118 (08) 2069-2077
    CrossrefPubMedGoogle Scholar
  • 22 Choi SY, Park H, Kang MK. et al. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol 2013; 11: 291
    CrossrefPubMedGoogle Scholar
  • 23 Fakhruddin N, Jabbour M, Novy M. et al. BRAF and NRAS mutations in papillary thyroid carcinoma and concordance in BRAF mutations between primary and corresponding lymph node metastases. Sci Rep 2017; 7 (01) 4666
    CrossrefPubMedGoogle Scholar
  • 24 Friguglietti CU, Dutenhefner SE, Brandão LG, Kulcsar MA. Classification of papillary thyroid microcarcinoma according to size and fine-needle aspiration cytology: behavior and therapeutic implications. Head Neck 2011; 33 (05) 696-701
    CrossrefPubMedGoogle Scholar
  • 25 Miccoli P, Minuto MN, Ugolini C. et al. Intrathyroidal differentiated thyroid carcinoma: tumor size-based surgical concepts. World J Surg 2007; 31 (05) 888-894
    CrossrefPubMedGoogle Scholar
  • 26 Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110 (01) 38-46
    CrossrefPubMedGoogle Scholar
  • 27 Virk RK, Van Dyke AL, Finkelstein A. et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol 2013; 26 (01) 62-70
    CrossrefPubMedGoogle Scholar
  • 28 Zheng X, Wei S, Han Y. et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol 2013; 20 (07) 2266-2273
    CrossrefPubMedGoogle Scholar
  • 29 Mercante G, Frasoldati A, Pedroni C. et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 2009; 19 (07) 707-716
    CrossrefPubMedGoogle Scholar